Update shared on 27 Nov 2025
Fair value Decreased 0.97%Analysts have slightly reduced their fair value estimate for Mankind Pharma from ₹2,725.59 to ₹2,699.12. They cite minor adjustments in projected revenue growth and profit margins as influencing factors.
What's in the News
- An upcoming Board Meeting is scheduled for November 6, 2025. The agenda includes considering and approving the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Key Developments).
Valuation Changes
- The Fair Value Estimate has decreased marginally from ₹2,725.59 to ₹2,699.12.
- The Discount Rate remains unchanged at 12.76%.
- The Revenue Growth forecast has risen slightly, moving from 12.90% to 12.97%.
- The Net Profit Margin has improved modestly, increasing from 18.48% to 18.65%.
- The Future P/E ratio has declined, shifting from 48.92x to 47.29x.
Have other thoughts on Mankind Pharma?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.